Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Xingrui He, Xiabin Chen, Hancheng Zhang, Tian Xie & Xiang-Yang Ye. (2019) Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opinion on Therapeutic Patents 29:2, pages 137-149.
Read now
Read now
Barry J Sheane & Vinod Chandran. (2014) Investigational drugs for treating psoriatic arthritis. Expert Opinion on Investigational Drugs 23:7, pages 1001-1016.
Read now
Read now
Peter Norman. (2014) Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum. Expert Opinion on Therapeutic Patents 24:3, pages 361-368.
Read now
Read now
Peter Norman. (2014) Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold. Expert Opinion on Therapeutic Patents 24:2, pages 231-237.
Read now
Read now
Brian W Dymock & Cheng Shang See. (2013) Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. Expert Opinion on Therapeutic Patents 23:4, pages 449-501.
Read now
Read now
Articles from other publishers (29)
Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang & Sheng Jiang. (2023) Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry 66:7, pages 4378-4416.
Crossref
Crossref
Sarveswara Rao Vangala, Navneet Bung, Sowmya Ramaswamy Krishnan & Arijit Roy. (2022) An interpretable machine learning model for selectivity of small-molecules against homologous protein family. Future Medicinal Chemistry 14:20, pages 1441-1453.
Crossref
Crossref
Mengyuan Li, Yu Yan, Xinxin Zhang, Yidan Zhang, Xiaohan Xu, Lei Zhang, Liangliang Lu, Jie Wang, Yazhuo Zhang, Qiaoling Song & Chenyang Zhao. (2021) Scaffold compound L971 exhibits anti‐inflammatory activities through inhibition of JAK/STAT and NFκB signalling pathways. Journal of Cellular and Molecular Medicine 25:13, pages 6333-6347.
Crossref
Crossref
Chilakamarti V. Ramana & Bikul Das. (2021) Profiling transcription factor sub-networks in type I interferon signaling and in response to SARS-CoV-2 infection. Computational and Mathematical Biophysics 9:1, pages 273-288.
Crossref
Crossref
Elham Y. Al-Barghouthy, Areej Abuhammad & Mutasem O. Taha. (2019) QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor. Medicinal Chemistry Research 28:9, pages 1368-1387.
Crossref
Crossref
Ana Martinez & Carmen Gil. 2019. Emerging Drugs and Targets for Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis
170
196
.
Hiroaki Yamagishi, Takayuki Inoue, Yutaka Nakajima, Jun Maeda, Hiroaki Tominaga, Hiroyuki Usuda, Takeshi Hondo, Ayako Moritomo, Fumihiro Nakamori, Misato Ito, Koji Nakamura, Hiroki Morio, Yasuyuki Higashi, Masamichi Inami & Shohei Shirakami. (2017) Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors. Bioorganic & Medicinal Chemistry 25:20, pages 5311-5326.
Crossref
Crossref
Atli Thorarensen, Martin E. Dowty, Mary Ellen Banker, Brian Juba, Jason Jussif, Tsung Lin, Fabien Vincent, Robert M. Czerwinski, Agustin Casimiro-Garcia, Ray Unwalla, John I. Trujillo, Sidney Liang, Paul Balbo, Ye Che, Adam M. Gilbert, Matthew F. Brown, Matthew Hayward, Justin Montgomery, Louis Leung, Xin Yang, Sarah Soucy, Martin Hegen, Jotham Coe, Jonathan Langille, Felix Vajdos, Jill Chrencik & Jean-Baptiste Telliez. (2017)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2
S
,5
R
)-5-((7
H
-Pyrrolo[2,3-
d
]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
. Journal of Medicinal Chemistry 60:5, pages 1971-1993.
Crossref
Crossref
Qunhao Hou, Ruiyue Gong, Xiancheng Liu, Huiling Mao, Xiaowen Xu, Dan Liu, Zao Dai, Haizhou Wang, Binhua Wang & Chengyu Hu. (2017) Poly I:C facilitates the phosphorylation of Ctenopharyngodon idellus type I IFN receptor subunits and JAK kinase. Fish & Shellfish Immunology 60, pages 13-20.
Crossref
Crossref
Róbert Kiss, Dávid Bajusz, Rebekah Baskin, Katalin Tóth, Katalin Monostory, Peter P. Sayeski & György M. Keserű. (2016) Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells. Archiv der Pharmazie 349:12, pages 925-933.
Crossref
Crossref
Wei Zhang, Jianzong Li, Zhixin Huang, Haiyang Wang, Hao Luo, Xin Wang, Nan Zhou, Chuanfang Wu & Jinku Bao. (2016) Computer-aided identification of potential TYK2 inhibitors from drug database. Journal of Molecular Structure 1122, pages 309-317.
Crossref
Crossref
Yutaka Nakajima, Naohiro Aoyama, Fumie Takahashi, Hiroshi Sasaki, Keiko Hatanaka, Ayako Moritomo, Masamichi Inami, Misato Ito, Koji Nakamura, Fumihiro Nakamori, Takayuki Inoue & Shohei Shirakami. (2016) Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3. Bioorganic & Medicinal Chemistry 24:19, pages 4711-4722.
Crossref
Crossref
Takatoshi Yogo, Hiroyuki Nagamiya, Masaki Seto, Satoshi Sasaki, Huang Shih-Chung, Yusuke Ohba, Norihito Tokunaga, Gil Nam Lee, Chul Yun Rhim, Cheol Hwan Yoon, Suk Young Cho, Robert Skene, Syunsuke Yamamoto, Yousuke Satou, Masako Kuno, Takahiro Miyazaki, Hideyuki Nakagawa, Atsutoshi Okabe, Shogo Marui, Kazuyoshi Aso & Masato Yoshida. (2016)
Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4
H
-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors
. Journal of Medicinal Chemistry 59:2, pages 733-749.
Crossref
Crossref
Woo Dae Jang, Jun-Tae Kim, Hoon Young Son, Seung Yeon Park, Young Sik Cho, Tae-sung Koo, Hyuk Lee & Nam Sook Kang. (2015) Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design. Bioorganic & Medicinal Chemistry Letters 25:18, pages 3947-3952.
Crossref
Crossref
Yutaka Nakajima, Takayuki Inoue, Kazuo Nakai, Koichiro Mukoyoshi, Hisao Hamaguchi, Keiko Hatanaka, Hiroshi Sasaki, Akira Tanaka, Fumie Takahashi, Shigeki Kunikawa, Hiroyuki Usuda, Ayako Moritomo, Yasuyuki Higashi, Masamichi Inami & Shohei Shirakami. (2015) Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorganic & Medicinal Chemistry 23:15, pages 4871-4883.
Crossref
Crossref
Hiroaki Yamagishi, Shohei Shirakami, Yutaka Nakajima, Akira Tanaka, Fumie Takahashi, Hisao Hamaguchi, Keiko Hatanaka, Ayako Moritomo, Masamichi Inami, Yasuyuki Higashi & Takayuki Inoue. (2015) Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. Bioorganic & Medicinal Chemistry 23:15, pages 4846-4859.
Crossref
Crossref
John S. Tokarski, Adriana Zupa-Fernandez, Jeffrey A. Tredup, Kristen Pike, ChiehYing Chang, Dianlin Xie, Lihong Cheng, Donna Pedicord, Jodi Muckelbauer, Stephen R. Johnson, Sophie Wu, Suzanne C. Edavettal, Yang Hong, Mark R. Witmer, Lisa L. Elkin, Yuval Blat, William J. Pitts, David S. Weinstein & James R. Burke. (2015) Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. Journal of Biological Chemistry 290:17, pages 11061-11074.
Crossref
Crossref
Christel J Menet, Oscar Mammoliti & Miriam López-Ramos. (2015) Progress toward JAK1-selective inhibitors. Future Medicinal Chemistry 7:2, pages 203-235.
Crossref
Crossref
Yutaka NakajimaTakashi TojoMasataka MoritaKeiko HatanakaShohei ShirakamiAkira TanakaHiroshi SasakiKazuo NakaiKoichiro MukoyoshiHisao HamaguchiFumie TakahashiAyako MoritomoYasuyuki HigashiTakayuki Inoue. (2015) Synthesis and Evaluation of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine Derivatives as Novel Immunomodulators Targeting Janus Kinase 3. CHEMICAL & PHARMACEUTICAL BULLETIN Chemical and Pharmaceutical Bulletin 63:5, pages 341-353.
Crossref
Crossref
Brian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva & Lianbin Yao. (2014) Selective JAK inhibitors. Future Medicinal Chemistry 6:12, pages 1439-1471.
Crossref
Crossref
Atli Thorarensen, Mary Ellen Banker, Andrew Fensome, Jean-Baptiste Telliez, Brian Juba, Fabien Vincent, Robert M. Czerwinski & Agustin Casimiro-Garcia. (2014) ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. ACS Chemical Biology 9:7, pages 1552-1558.
Crossref
Crossref
Christel J Menet. (2014) Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. Pharmaceutical Patent Analyst 3:4, pages 449-466.
Crossref
Crossref
James D. Clark, Mark E. Flanagan & Jean-Baptiste Telliez. (2014) Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. Journal of Medicinal Chemistry 57:12, pages 5023-5038.
Crossref
Crossref
Raimund M. Vielnascher, Eva Hainzl, Nicole R. Leitner, Michael Rammerstorfer, David Popp, Agnieszka Witalisz, Rita Rom, Marina Karaghiosoff, Thomas Kolbe, Simone Müller, Thomas Rülicke, Caroline Lassnig, Birgit Strobl & Mathias Müller. (2014) Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Research 23:3, pages 519-529.
Crossref
Crossref
Eva Salgado, Jose R Maneiro, Loreto Carmona & Juan J Gomez-Reino. (2014) Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Annals of the Rheumatic Diseases 73:5, pages 871-882.
Crossref
Crossref
Charles J Malemud. (2014) Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World Journal of Orthopedics 5:4, pages 496.
Crossref
Crossref
Soumya D. Chakravarty, Poulikos I. Poulikakos, Lionel B. Ivashkiv, Jane E. Salmon & George D. Kalliolias. (2013) Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis. Clinical Immunology 148:1, pages 66-78.
Crossref
Crossref
Lorena Fontan & Ari Melnick. (2013) Discovering What Makes STAT Signaling TYK in T-ALL. Cancer Discovery 3:5, pages 494-496.
Crossref
Crossref
Hae-Rim Kim. (2013) Phosphoinositide 3-kinase (PI3K) as a New Therapeutic Target for Rheumatoid Arthritis. Journal of Rheumatic Diseases 20:2, pages 74.
Crossref
Crossref